Cost-effectiveness of ferric carboxymaltose in patients with iron deficiency and chronic heart failure in Austria

Evelyn Walter, Marlies Bauer, Sandra Ressl
IPF Institute for Pharmaco-Economic Research, Vienna, Austria

Objective
Iron deficiency (ID), a non-cardiovascular comorbidity, is highly prevalent in chronic heart failure (CHF) patients and imposes a significant disease burden for CHF patients with iron deficiency with and without anemia. The purpose of this study was to evaluate the cost-effectiveness of FCM versus no treatment and oral supplementation in CHF patients with iron deficiency with and without anemia.

Methods
We developed a Cost-Utility-Model to simulate disease progression in CHF patients using different strategies of iron deficiency management. Markov modelling techniques were used to estimate disease progression, based on health state, defined by NYHA classes and death. Monte Carlo simulation accounted for uncertainty. The model includes 5 states and monthly transitions. Probabilities were derived from clinical and epidemiological studies. The cohort definition was adapted from the FAIR-HF study. Direct costs (NYHA, inpatient, outpatient and iron treatment costs) from published sources were used and expressed in Euro (2014) from the payer's perspective. QALYs and total costs were projected over a 4-year time horizon and discounted at 5% p.a.

Clinical Data
Transition probabilities for movement between NYHA classes of heart failure for the no treatment strategy were estimated from the published literature (Yao et al. 2008, Ford et al. 2012). Changes of NYHA classes of the starting cohort represents the Austrian distribution (calculated based on Klip et al. 2013 and Klip et al. 2014). Patients progressed through the model in 1 month cycles for a duration of 4 years. After 1 year, patients either remained in NYHA class, improved or deteriorated. Patients could die in each health state. CHF patients could receive 3 different strategies: FCM, oral treatment or no iron treatment.

Resource Use and Costs
Data on the resource use of the included iron deficiency and CHF was collected in two steps. First, the medical resources were derived by literature (e.g. clinical trials like FAIR-HF, cohort studies including patients with CHF, treatment guidelines etc.). In a second step this literature review was transferred to the Austrian setting. The following direct medical costs were included:

- NYHA costs: patients in NYHA II have about 14% increased costs compared with NYHA I, NYHA III by 48% and NYHA IV by 71%.
- Medication costs: dosage equivalents of FCM and oral treatments were calculated based on the Ganzoni formular.
- Outpatient costs: GP consultations and blood count
- Inpatients costs: hospitalization due to iron deficiency

Austrian costs were derived from a number of publicly available sources like the DRG catalogue (LKF), official price lists for the Austrian Health insurances and the Austrian official drug price list (Warenverzeichnis). When necessary, prices were adjusted to 2014 prices using the consumer price index.

Results
Over a 4-year timeframe, costs and outcomes associated with FCM would amount to €18,797.39 and 2.46 QALYs. Costs associated with oral treatment are €17,307.06 and 2.37 QALYs (ICER per QALY gained: €16,922). Costs and outcomes associated with no treatment are €17,934.15 and 2.3 QALYs (ICER per QALY gained: €5,411). Due to a delayed disease progression in the FCM group NYHA costs are lower than with oral replacement and no treatment.

The analysis shows that iron deficiency therapy leads to reduced NYHA and hospitalization costs. Iron treatment costs are partly offset.

Sensitivity Analysis
Uncertainty is addressed in the model using probabilistic sensitivity analysis. Statistical distributions were assigned to key model parameters to examine second-order uncertainty in the estimation of the parameter. Uncertainty was propagated through the model using Monte Carlo simulation, drawing parameter values at random 500 times from the particular distributions.

Conclusion
IV iron treatment with FCM compared with oral iron in iron deficient CHF patients is clearly below the CE threshold of € 22,250 - € 33,300/QALY typically used by the UK NICE and hence can be considered a cost effective treatment strategy.

References

Acknowledgement
In this study, we would like to thank ViFör for their financial support. Additional information with the author.

This study was supported by ViFör.